DrugDashboards

Propofol

Propofol · PROPOFOL 10 mg/mL · Injection, Emulsion · Intravenous · Hospira, Inc.

NDC 00409-6010-25 · 25 VIAL in 1 TRAY / 20 mL in 1 VIAL · ANDA · View full market →

The short version

13 companies supply this market — deep enough that no single failure threatens the supply. The price is up 24% over the past year, to $0.1709 per mL. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.1709per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.0890per billing unit (10 MG)HCPCS J2704 · Jul 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.1$0.2Jun 2024Sep 2026$0.1709
11 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$108.05
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 10 MG
$0.089
HCPCS J2704 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$256,088
29,666 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10● Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for propofol (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA077908
TE code
AB
Approval date
Mar 17, 2006
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class I · TerminatedAug 22, 2022
    Pfizer Inc. — Presence of particulate matter
  • Class I · TerminatedJul 13, 2022
    Pfizer Inc. — Presence of particulate matter: particulate identified as a beetle.
  • Class II · TerminatedDec 23, 2014
    Hospira Inc. — Presence of Particulate Matter: The firm received a complaint of an embedded particulate in the neck of one vial composed primarily of iron.
  • Class I · TerminatedOct 6, 2014
    Hospira Inc. — Temperature Abuse: Products experienced uncontrolled temperature excursions during transit.
  • Class I · TerminatedApr 2, 2014
    Hospira Inc. — Presence of Particulate Matter: A glass defect was found on the interior neck of the vial during a retain sample inspection where the glass vial contained visible embedded metallic particulate and free floating metallic particulates were also found in solution.
  • Class II · TerminatedDec 12, 2013
    Hospira Inc. — Presence of Particulate Matter: Glass defect located on the interior neck of the vial identified glass surface abrasions and visible embedded particulate matter which could result in the potential for small glass flakes or embedded metal particulate to become dislodged into the solution.
  • Class II · TerminatedOct 11, 2013
    Hospira Inc. — Presence of Particulate Matter: Visible particles embedded in the glass identified during a retain sample inspection.
  • Class II · TerminatedAug 14, 2013
    Hospira Inc. — Presence of Particulate Matter: Visible particulate embedded in the glass vial was observed and confirmed in a sample bottle during retain sample inspection.
  • Class II · TerminatedMay 25, 2013
    Hospira Inc. — Presence of Particulate Matter; single visible particulate was identified during a retain sample inspection identified as stainless steel
  • Class II · TerminatedApr 8, 2013
    Hospira Inc. — Presence of Particulate Matter: A single visible particulate was identified during a retain sample inspection.
  • Class II · TerminatedFeb 25, 2013
    Hospira Inc. — Presence of Particulate Matter: Visible particulate embedded in vials was observed and confirmed in a sample bottle during retain inspection.
  • Class II · TerminatedNov 15, 2012
    Hospira Inc. — Presence of Particulate Matter: Visible particulate and particulate embedded in vials were observed during retain inspection.
  • Class II · TerminatedAug 29, 2012
    Hospira Inc. — Presence of Particulate Matter: A single visible particulate was observed and confirmed in sample bottles of the recalled lots during retain inspection.
  • Class II · TerminatedAug 3, 2012
    Hospira Inc. — Presence of Particulate Matter: A single visible particulate was observed and confirmed in a sample bottle during retain inspection.
  • Class II · TerminatedApr 11, 2012
    Hospira, Inc. — Presence of Particulate Matter: A single visible particulate was observed in a retention sample bottles identified as stainless steel

Manufacturers of Propofol (Injection, Emulsion)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals Private LimitedPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Avenacy, LLCPROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsPROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Civica, IncPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Hikma Pharmaceuticals USA Inc.PROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
NorthStar Rx LLCPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Pfizer Laboratories Div Pfizer IncPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Anthea Pharma Private LimitedPROPOFOL 10 mg/mLJul 18, 2026Aug 29, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Propofol — NDC 00409-6010-25," retrieved September 3, 2026, https://drugdashboards.com/drug/00409601025.

Free to cite with attribution — see how the data is put together.